PRIM (is still alive and well) 06/30/2023 MA
Post# of 7795
(Total Views: 184)
Posted On: 08/07/2023 11:48:56 AM
PRIM (is still alive and well)
06/30/2023
MADRID (EP). Prim's ordinary general shareholders' meeting has endorsed the distribution to shareholders of an amount amounting to 2.5 million euros, which completes the payment of the total dividend of 6.24 million euros, as well as the appointment of its director general, Fernando Oliveros Arreaga, as executive director of the company for a period of four years. Specifically, the Prim group has agreed to distribute the remaining 2.4 million on July 13, while explaining that shareholders who have acquired shares in the company until July 10 will be entitled to the dividend pending payment, that is, , two business days immediately prior to the aforementioned payment date.
The shareholders have also ratified Juan Jesús González Prim as proprietary director of the company, Jorge Prim Martínez as proprietary director and Belén Amatriain Corbi as independent. Among other issues, the annual accounts and the management report of the company and its group, corresponding to the financial year 2022, have been submitted for examination and approval at the meeting.
The proposal to apply the result for the 2022 financial year was also voted on, as well as the proposal for a long-term incentive plan, with a duration of four years and aimed at executive directors and managers of Grupo Prim. Likewise, the company has approved a long-term incentive plan, including cash and shares, which will amount to 1.2 million euros.
The company registered a gross operating result (Ebitda) of 6.6 million euros during the first quarter of this year, which represents an improvement of 20.8% compared to the same period of the previous year, driven by the "significant" increase in turnover and containment of costs.
Thus, the company closed the first quarter with a turnover of 54 million euros, 15% higher than that registered in the same period of 2022, due to the organic growth of the businesses, which accounted for 9% with a " positive" evolution of traditional products and new launches, as well as the good progress of the companies acquired in previous years to comply with the 2021-2025 Strategic Plan.
New launches?
Must include RecoveryRX!
06/30/2023
MADRID (EP). Prim's ordinary general shareholders' meeting has endorsed the distribution to shareholders of an amount amounting to 2.5 million euros, which completes the payment of the total dividend of 6.24 million euros, as well as the appointment of its director general, Fernando Oliveros Arreaga, as executive director of the company for a period of four years. Specifically, the Prim group has agreed to distribute the remaining 2.4 million on July 13, while explaining that shareholders who have acquired shares in the company until July 10 will be entitled to the dividend pending payment, that is, , two business days immediately prior to the aforementioned payment date.
The shareholders have also ratified Juan Jesús González Prim as proprietary director of the company, Jorge Prim Martínez as proprietary director and Belén Amatriain Corbi as independent. Among other issues, the annual accounts and the management report of the company and its group, corresponding to the financial year 2022, have been submitted for examination and approval at the meeting.
The proposal to apply the result for the 2022 financial year was also voted on, as well as the proposal for a long-term incentive plan, with a duration of four years and aimed at executive directors and managers of Grupo Prim. Likewise, the company has approved a long-term incentive plan, including cash and shares, which will amount to 1.2 million euros.
The company registered a gross operating result (Ebitda) of 6.6 million euros during the first quarter of this year, which represents an improvement of 20.8% compared to the same period of the previous year, driven by the "significant" increase in turnover and containment of costs.
Thus, the company closed the first quarter with a turnover of 54 million euros, 15% higher than that registered in the same period of 2022, due to the organic growth of the businesses, which accounted for 9% with a " positive" evolution of traditional products and new launches, as well as the good progress of the companies acquired in previous years to comply with the 2021-2025 Strategic Plan.
New launches?
Must include RecoveryRX!
(1)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼